Vladimir Stojiljkovic, M.D., Ph.D.
Braničevska 13 (kod Hrama), 11000 Beograd – Serbia
dr.stojiljkovic(at)yahoo.com

 

Method: Twenty women wore the Brava device, a bra-like vacuum-based external tissue expander, for 4 weeks and then underwent autologous fat injection using 10 to 14 needle puncture sites into each breast in a three-dimensional fanning pattern (average, 252 ml volume injected per breast). Patients resumed Brava wear within 24 hours for 7 or more days. Pretreatment and posttreatment breast volumes were derived from three-dimensional volumetric reconstruction of magnetic resonance imaging scans. Follow-up ranged from 6 months to 3 years. In two patients additional fat transfer was done.
Results: Breast volume was unchanged between 3 and 6 months. All of the treated women were compliant with Brava. Graft survival was 78±16 percent. There was a strong linear correlation between pregrafting Brava expansion and the resultant breast augmentation. There were no suspicious breast masses or nodules.
Conclusion: The addition of Brava expansion before autologous fat grafting leads to significantly larger breast augmentations, with more fat graft placement, higher graft survival rates, and minimal graft necrosis or complications, demonstrating high safety and efficacy for the procedure.